Gufic Biosciences Limited (NSE:GUFICBIO)

Market Cap	36.20B
Revenue (ttm)	8.10B
Net Income (ttm)	819.76M
Shares Out	n/a
EPS (ttm)	8.17
PE Ratio	44.15
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 17, 2024

Volume	372,674
Average Volume	67,784
Open	362.80
Previous Close	361.05
Day's Range	360.95 - 407.15
52-Week Range	278.00 - 504.25
Beta	0.72
RSI	65.48
Earnings Date	May 29, 2025

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 1,491
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUFICBIO

Financial Performance

In 2023, Gufic Biosciences's revenue was 8.07 billion, an increase of 16.80% compared to the previous year's 6.91 billion. Earnings were 861.36 million, an increase of 8.07%.